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rtery Stenosis
here’s Waldo?*
atrick L. Whitlow, MD, FACC
leveland, Ohio
e have all treated patients who dramatically improve
eclining renal function, previously uncontrollable hyper-
ension, or episodic flash pulmonary edema after stenting a
evere atherosclerotic renal artery lesion(s). Experience with
hese success stories has proven that atherosclerotic renal
rtery stenosis (RAS) in some patients (the Waldos in the
rowd of patients with atherosclerotic RAS) can impair
enal perfusion and activate the renin-angiotensin system to
mplify hypertension. However successful stenting of ath-
rosclerotic renal artery lesions rarely cures hypertension and
mproves blood pressure in only 50% to 70% of patients (1),
hereas renal function is improved in only 25% of those
ith impaired glomerular filtration at baseline (2). In fact,
enal function deteriorates in 10% to 20% of patients after
successful” stenting. Many different issues contribute to
linical outcome after renal artery stenting, and more
eliable predictors for selecting patients who are likely to
linically benefit from stenting atherosclerotic RAS are
eeded. We should require more than simply visualizing a
tenosis before stenting is performed (3).
See page 286
Renal artery angiography is often performed in a single-
lane projection without orthogonal views. The stenosis
sually begins at the aorto-ostial junction and is eccentric,
oth factors making quantification imprecise. It is likely that
ome patients undergoing renal artery stenting do not in fact
ave a severely flow-limiting stenosis. Mitchell et al. (4)
easured renal artery fractional flow reserve (FFR) after
apaverine-induced hyperemia in 17 patients with uncon-
rolled hypertension and atherosclerotic lesions. Patients
ith an FFR 0.8 had subsequent blood pressure improve-
ent in 86% of patients after stenting, compared with 30%
ith improvement in those with FFR 0.8. In that study,
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-c
ions or the American College of Cardiology.
From the Cleveland Clinic Foundation, Cleveland, Ohio.uantitative angiography was not able to predict responders
rom nonresponders even though FFR was able to. Thus,
recise functional assessment might help in the selection of
atients more likely to improve after renal artery stenting in
he future. More scientific information is needed to clarify
he role of FFR measurement in patient selection for
therosclerotic renal artery stenting (5).
Even significant RAS does not always cause hypertension
n an individual patient. Essential hypertension might be
he predominant factor in some (many?) of these patients.
enal dysfunction is especially common in elderly hyper-
ensive patients, and renal failure alone without RAS can
ause hypertension. Because renal function remains un-
hanged in most patients after successful stenting, this
ontributor to hypertension remains unchanged in the
ajority of patients presenting with renal dysfunction and
therosclerotic RAS. It is likely that a significant number of
atients with co-existent RAS and hypertension do not have
ow limitation as their major stimulus for elevated blood
ressure.
Although theoretically appealing, documentation of acti-
ation of the renin-angiotensin system has not been consis-
ently predictive of a favorable response to renal artery
tenting. Even in 2-kidney-1-clip experimental hyperten-
ion, activation of multiple compensatory mechanisms can
ormalize renin in the chronic phase of established hyper-
ension. Elevated Doppler-derived renal resistive index was
nitially touted as a predictor of a poor response to renal
tenting, but subsequent data suggest this is not the case.
levated brain natriuretic peptide (BNP) in the absence of
eart failure might be a clue that RAS is significant in some
atients (3), but diastolic dysfunction is so common in
ypertensive atherosclerotic RAS patients that the predic-
ive accuracy of an elevated BNP for improvement after
tenting is likely to be low. Thus, we do not have, with the
ossible exception of FFR, a sensitive or specific test to
redict the response of an individual patient to renal artery
tenting.
In contrast to the improvement in percent stenosis that
e reliably see after renal artery stenting, we might also
mbolize atherosclerotic debris distally into the renal paren-
hyma, impairing renal function in some patients. Emboli-
ation can be identified by angiography in a minority of
atients, but angiographically silent emboli could worsen
enal function and/or exacerbate hypertension. Even today
here is no consensus that emboli protection devices are
seful in renal artery stenting. The CORAL (Cardiovascu-
ar Outcomes in Renal Atherosclerotic Lesions) trial ini-
ially required renal artery protection during stenting, but
his requirement has been changed to an option at the
iscretion of the individual operator. Renal protection
evices have not been systematically evaluated, and no
pecific protection device has been developed for the renal
irculation. Despite the fact that emboli protection devices
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294ave been used for more than 8 years in other vascular beds,
o prospective randomized trial has been conducted in renal
rteries, and the possible efficacy of renal emboli protection
emains unknown.
Because of the enthusiasm of interventional cardiologists
or stenting renal artery atherosclerotic lesions, we have
ome under attack from nephrologists and the rest of the
onservative medical community. This criticism is not
ithout substance. The Dutch multi center DRASTIC trial
ailed to show an improvement with renal artery angioplasty
ver medical therapy (6). The preliminary results of the
STRAL trial recently presented at the American College
f Cardiology meeting in 2008 also suggested no improve-
ent in blood pressure control or renal function with renal
rtery stenting versus medical therapy in patients with RAS
nd no “clear indication” for stenting. “Clear indications”
ncluded pulmonary edema and acute renal failure in asso-
iation with severe RAS (7). The onus has now clearly
hifted to the interventional community to scientifically
efine which patients might benefit from atherosclerotic
enal artery stenting and whether emboli protection devices
re of value in preserving renal function.
In this issue of JACC: Cardiovascular Interventions, Mah-
ud et al. (8) present results on renal frame count and renal
lush grade as quantitative measures to predict the success
f renal stenting to improve hypertension. The authors used
tandard angiographic methods validated in the coronary
orld to assess renal flow by quantitative angiography.
igital angiograms acquired at 30 frames/s and analyzed
ffline by the method first described by Mulumudi and
hite (9) in hypertensive renal fibromuscular disease pa-
ients were used. Hypertensive patients with unilateral RAS
ad an elevated baseline renal frame count of 26.6  9.1
normal  20.1  5.4) frames/s, and renal frame count was
educed to 21.4  6.7 after stenting (p  0.001). Clinical
esponders identified as those with a systolic blood pressure
eduction 15 mm had a decrease in renal frame count of
.7  4.6 compared with 1.7  5.1 frames/s in nonre-
ponders( p  0.009). More than 78% of patients with 4
rames/s renal frame count decrease after successful stenting
ere responders. The study is limited in patient numbers,
ut the results suggest that reduced renal artery perfusion
eflected by increased renal frame count might predict those
atients most likely to respond to renal artery stenting with
n improvement in blood pressure. A reduction in renal
rame count 4 frames/s also predicted a good clinical
esponse. These hypothesis-generating data require further
alidation, but it involves a method (digital angiography)
hat we all have available but have not used extensively. Not
ll laboratories performing renal stenting use 30-frames/sigital acquisition, but this could be standardized easily and
tudied prospectively.
In addition, Mahmud et al. (8) measured renal blush
rade before and after stenting. They noted a low renal
lush grade at baseline (1.63  0.71; normal  2.33 
.66) that was improved after renal stenting to 2.13  0.85
p 0.03). Although renal blush grade was not predictive of
linical response in this small study, one might hypothesize
hat reduction in renal blush grade after stenting might
rovide a quantitative index of the extent of distal emboli-
ation. Such a surrogate end point might be helpful in
larifying the potential benefit of emboli protection devices
n renal artery stenting in the future.
The authors are to be congratulated on this scientific
ndeavor to identify quantitative measures that might help
s in defining the role of renal artery stenting for athero-
clerotic lesions in the future. A renewed effort of interven-
ionalists to study the effects of renal artery stenting carefully
nd scientifically needs to be mounted in order to clarify the
ossible role of stenting in atherosclerotic renal artery
isease.
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